Education
About Us
Working with TipRanks
Follow Us
BioInvent International AB (SE:BINV)
:BINV
Total Valuation
BioInvent International AB has a market cap or net worth of kr1.52B. The enterprise value is kr1.17B.
Market Capkr1.52B
Enterprise Valuekr1.17B
Share Statistics
BioInvent International AB has 65,804,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,804,360
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioInvent International AB’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -62.07%.
Return on Equity (ROE)-0.60
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-62.07%
Return on Capital Employed (ROCE)-0.63
Revenue Per Employee1.92M
Profits Per Employee-2.82M
Employee Count118
Asset Turnover0.34
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioInvent International AB is ―. BioInvent International AB’s PEG ratio is 0.26.
PE Ratio―
PS Ratio8.54
PB Ratio3.47
Price to Fair Value3.47
Price to FCF-7.58
Price to Operating Cash Flow-6.14
PEG Ratio0.26
Income Statement
In the last 12 months, BioInvent International AB had revenue of 226.50M and earned -332.86M in profits. Earnings per share was -5.06.
Revenue226.50M
Gross Profit226.50M
Operating Income-351.39M
Pretax Income-332.46M
Net Income-332.86M
EBITDA-331.52M
Earnings Per Share (EPS)-5.06
Cash Flow
In the last 12 months, operating cash flow was -247.75M and capital expenditures -7.26M, giving a free cash flow of -255.01M billion.
Operating Cash Flow-247.75M
Free Cash Flow-255.01M
Free Cash Flow per Share-3.88
Dividends & Yields
BioInvent International AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change-23.64%
50-Day Moving Average27.29
200-Day Moving Average31.35
Relative Strength Index (RSI)38.98
Average Volume (3m)91.72K
Important Dates
BioInvent International AB upcoming earnings date is Apr 29, 2026, Before Open (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateApr 29, 2026
Ex-Dividend Date―
Financial Position
BioInvent International AB as a current ratio of 5.67, with Debt / Equity ratio of 1.74%
Current Ratio5.67
Quick Ratio5.56
Debt to Market Cap<0.01
Net Debt to EBITDA1.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BioInvent International AB has paid 397.00K in taxes.
Income Tax397.00K
Effective Tax Rate>-0.01
Enterprise Valuation
BioInvent International AB EV to EBITDA ratio is -4.79, with an EV/FCF ratio of -6.23.
EV to Sales7.01
EV to EBITDA-4.79
EV to Free Cash Flow-6.23
EV to Operating Cash Flow-6.41
Balance Sheet
BioInvent International AB has kr592.75M in cash and marketable securities with kr9.68M in debt, giving a net cash position of kr583.06M billion.
Cash & Marketable Securitieskr592.75M
Total Debtkr9.68M
Net Cashkr583.06M
Net Cash Per Sharekr8.86
Tangible Book Value Per Sharekr8.48
Margins
Gross margin is 98.53%, with operating margin of -155.14%, and net profit margin of -146.96%.
Gross Margin98.53%
Operating Margin-155.14%
Pretax Margin-146.79%
Net Profit Margin-146.96%
EBITDA Margin-146.37%
EBIT Margin-155.14%
Analyst Forecast
The average price target for BioInvent International AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast533.73%
EPS Growth Forecast20.92%